Veracyte Announces Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Veracyte (VCYT) Tops Q3 EPS by 13c, Revenues Beat; Boosts FY18 Revenue Outlook
October 29, 2018 4:30 PM EDTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.12), $0.13 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $21.5 million.
Revenue was $23.5 million, an increase of 34 percent;Genomic test volume was 8,006, an increase of 23 percent;Gross margin was 65 percent, an increase of 6 percent;Operating expenses,... More